MDM4 and hepatocellular carcinoma: Nevertheless, subgroups of HCC patients may benefit from targeting the MDM4 transcription, arguing for HCC patients to be included in early clinical studies evaluating the clinical potential of pharmacological MDM4 inhibitors.